Category - News

Markets

Stifel ups Capital Senior Living to hold; maintains PT $8.50

Stifel upgraded Capital Senior Living (NYSE:CSU) to “hold” from “sell” but maintained its price target of $8.50, saying the shares have overshot its fair value estimates. The stock closed at $8.34 on August 23. “We...

August 24, 2018

Developments

Sierra Oncology acquires momelotinib from Gilead

Sierra Oncology (NASDAQ:SRRA) has acquired the drug candidate, momelotinib, from Gilead Sciences (NASDAQ:GILD) for a $3-million upfront fee and potential milestone payments of up to $195-million, which are largely...

August 22, 2018

Markets

Leerink starts Neogenomics at OP; PT $18

Leerink initiated coverage of Neogenomics (NASDAQ:NEO) with an “outperform” rating and price target of $18. The stock closed at $12.84 on August 20. Analyst Puneet Souda writes that Neogenomics is a “uniquely positioned...

August 21, 2018

Markets

Roth cuts Lannett Co. to neutral; PT to $8 from $23

Roth Capital Partners downgraded Lannett Co. (NYSE AMER:LCI) to “neutral” and slashed its price target to $8 from $23 after the company lost an important customer and issued a profit warning. Near midday on August 20...

August 20, 2018

Markets

Needham starts Liquidia Technologies at buy; PT $30

Needham initiated coverage of Liquidia Technologies (NASDAQ:LQDA) with a “buy” rating and $30 price target. The stock closed at $14.90 on August 17. Liquidia is developing LIQ861, a differentiated inhaled treatment for...

August 20, 2018

Markets

Ladenburg starts Achieve Life Sciences at buy; PT $12

Ladenburg Thalmann initiated coverage of Achieve Life Sciences (NASDAQ:ACHV) with a “buy” rating and $12 price target. The stock finished at $2.80 on August 17. Achieve is developing cytisine, a natural compound with...

August 20, 2018

Executive Moves

Scott Smith joins board of Spring Bank Pharma

Spring Bank Pharmaceuticals (NASDAQ:SBPH) named Scott Smith as an independent member of the board, replacing Jonathan Bates, who is stepping down as a director after 10 years of service with the company.

August 17, 2018

Developments

FDA accepts Evoke Pharma NDA for Gimoti; PDUFA date April 1

The FDA has accepted for review Evoke Pharma’s (NASDAQ:EVOK) 505(b)(2) NDA for Gimoti, the company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic...

August 16, 2018

Markets

HCW starts AVEO Pharma at buy; PT $6.50

H.C. Wainwright initiated coverage of AVEO Pharmaceuticals (NASDAQ:AVEO) with a “buy” rating and $6.50 price target. The stock finished at $2.18 on Aug. 15.

August 16, 2018

Markets

Ladenburg starts AcelRx Pharma at buy; PT $7

Ladenburg Thalmann launched coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and price target of $7. The stock closed at $2.95 on August 15. AcelRx is focused on the development of acute pain...

August 16, 2018

Category - News

Subscribe